Amoxicillin Sodium 500mg powder for solution for injection - additional reports of injection site reactions in paediatrics and adults

(Wockhardt UK Ltd) Remaining stock from affected batches should be quarantined and returned to the original supplier for credit - class 2 action within 48 hours. (EL (14)A/11)

22 July 2014

Class 2 medicines recall

Action Within 48 Hours

Hospital pharmacy and ward-level recall

MDR 43-06/14

Product details

Wockhardt UK Ltd

Amoxicillin Sodium 500mg Powder for Solution for Injection

PL 29831/0012

Alert details

Batch number Expiry date Pack size First distributed
1WA4002 Ìý 31 Jan 2017 Ìý 10 x 500mg Ìý 14 Apr 2014
1WA4003 Ìý 31 Jan 2017 Ìý 10 x 500mg Ìý 28 Feb 2014
1WA4004 Ìý 31 Jan 2017 Ìý 10 x 500mg Ìý 15 Apr 2014

Further to the , Wockhardt UK Ltd has received a small number of additional reports of injection site reactions in both paediatrics and adults. As a precaution, the above batches of the 500mg presentation are now being recalled. »Ê¹ÚÌåÓýapp investigation by Wockhardt and its contract manufacturer in Italy is ongoing and at this time, there is no evidence to suggest that these batches are defective.

Remaining stock from the affected batches should be quarantined and returned to the original supplier for credit. For enquiries relating to stock returns please contact Wockhardt UK Ltd Customer Services on 01978 669215 or email [email protected].

For medical information enquiries please contact Wockhardt UK Ltd Medical Information on 01978 661261 or email [email protected]

Please note, the advice given in EL (14)A/09 still applies. That is, the following products (all batches) should not be administered to neonates or infants (below 1 year old) until further notice:

  • Amoxicillin Sodium 250mg Powder for Solution for InjectionÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý PL 29831/0010
  • Amoxicillin Sodium 500mg Powder for Solution for InjectionÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý PL 29831/0012
  • Amoxicillin Sodium 1G Powder for Solution for InjectionÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý ÌýÌýÌý PL 29831/0011

Recipients of this drug alert should bring it to the attention of relevant contacts by copy of this letter.

Download documents

Updates to this page

Published 17 December 2014